Evidence brief · Supplement
Resveratrol for Longevity / healthspan
Evidence grade D — No human evidence
- Overall grade
- Grade D
- Last revised
- 1
- graded outcome
- 0
- references listed
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
1 at grade D — 1 graded row
What is known
Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.
- Longevity / healthspanEvidence grade D
No human evidence
Unclearlow
What is uncertain
Read off the same rows as above. Nothing here is added that the entry does not itself record.
- Thin evidence: Longevity / healthspan (grade D).
The evidence in words
The verdict
For longevity / healthspan, Resveratrol earns evidence grade D (unclear effect, low consistency) — the evidence does not support the claim. No human evidence
How it might work
It was proposed to activate SIRT1 and mimic caloric restriction; in humans the effects are small, inconsistent, and complicated by poor bioavailability.
How to use it
150–500 mg/day if trialing; expectations should be low.
Safety & cautions
Generally safe; mild antiplatelet effect and possible estrogenic activity at high doses.
Bottom line
The compound that started the longevity-supplement era and then disappointed. Human data are weak; spend elsewhere.
How it is used
As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.
- If trialing
- 150–500 mg/day.
Goes with
- ResveratrolRead the full Resveratrol monographEvidence grade D
Related reading
Entries that share this one's tags or conditions.
- Resveratrol for Metabolic markersEvidence grade D — InconsistentEvidence grade D
- PQQ for Fatigue / cognitionEvidence grade D — Weak, small studiesEvidence grade D
- Resveratrol: dosage and how to take it150–500 mg/day.Evidence grade D
- Resveratrol: side effects, safety & interactionsGenerally safe; mild antiplatelet effect and possible estrogenic activity at high doses.Evidence grade D
Sources
This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.
Last revised . A grade is this entry's reading of the evidence, not medical advice.